Logo
Login

Company Executives

$ Management Team

Dr. Anand Mehra

Non-Executive Independent Chairman of the Board

Age 48
Compensation $354.6K USD
Sex Male

Dr. Sven Lundberg

President

Chief Executive Officer

Executive Director

Age 60
Compensation $5.745M USD
Sex Male

Mr. Gregory Perry

Chief Financial Officer

Age 63
Compensation $301.0K USD
Sex Male

Dr. Fabian Zohren

Chief Medical Officer

Age 48
Compensation -
Sex Male

Mr. Peter Silverman

Chief Operating Officer

General Counsel

Chief Intellectual Property Officer and Head of US Legal

Age 45
Compensation $1.968M USD
Sex Male

Ms. Sherri Spear

Investor Relations and Corporate Communications

Age -
Compensation -
Sex Female

Board of Directors

From the proxy statement filed Apr 24, 2025
Directors
8
serving now
Independent
0 of 1
stated in the proxy; 7 not stated
Average tenure
6.1 years
from year joined
CEO also chairs the board
No
Anand Mehra
Director Age On board Independent Committees Other public boards 2024 pay Source
Anand Mehra
Board chair
 49 2015
10 years
 Not stated
Nomination and Corporate Governance Committee · Chair
Aclaris $472,201
Maxine Gowen
Not stated 2021
4 years
 Not stated
Audit Committee
Aclaris, Passage Bio Not stated
Mark Iwicki
57 2015
10 years
 Not stated
Compensation Committee · Chair
Akero Therapeutics, Inc., Q32 Bio, Inc. $366,220
Len Kanavy
64 2018
7 years
 Not stated
Compensation Committee
None stated $358,495
Sven (Bill) Ante Lundberg
CEO
 60 2019
6 years
 Not independent None stated Vor Biopharma Paid as CEO
Victor Sandor
57 2019
6 years
 Not stated None stated ADC Therapeutics, Istari Oncology, Prelude Therapeutics, Kymera Therapeutics $371,807
Jason Haddock
55 2024
1 year
 Not stated None stated PYC Therapeutics $640,098
Paolo Pucci
63 2020
5 years
 Not stated
Compensation Committee
West Pharmaceuticals Services, Inc., Replimmune Group Inc. $363,274

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 24, 2025 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans